Tests EEG monitoring during nasal dexmedetomidine sedation in children
Tests whether EEG readings can guide the sedation dose for children having brain MRI.
Plain-language title generated from the registry record
Registry title: Study of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring
Key facts
- Where
- Metz, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 18 years old?
Source: NCT06867289, who can take part
Where in France
- CHR Metz-Thionville Hopital Femme-Mère EnfantMetz, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Régional Metz-Thionville
- Trial code
- NCT06867289
- Record updated
- 12 March 2026
- Original description
This is a prospective, monocentric diagnostic study aiming to evaluate whether a sedation score obtained by a per-procedural electroencephalogram (EEG), the PSI score, could identify patients for whom a 2 μg/kg dose of DEX would not be sufficient for the successful performance of cerebral NMRI, and who could therefore benefit from a higher dosage of DEX (4 μg/kg).Read full original descriptionShow less
Study of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring
This is a prospective, monocentric diagnostic study aiming to evaluate whether a sedation score obtained by a per-procedural electroencephalogram (EEG), the PSI score, could identify patients for whom a 2 μg/kg dose of DEX would not be sufficient for the successful performance of cerebral NMRI, and who could therefore benefit from a higher dosage of DEX (4 μg/kg).
Inclusion: Indication of DEX sedation for brain NMRI at the CHR de Metz-Thionville; in a patient aged between 12 months and 5 years or; for a patient aged between 5 and 18 whose cooperation during the examination appears compromised (previous failure, autism spectrum disorders, etc.); Membership of a social security scheme; Free and informed consent obtained from the patient's legal guardian(s).
Exclusion: Patients with contraindications to the use of DEX; Hypersensitivity to the active ingredient or to any of the excipients listed in the section on "Hypersensitivity"; Advanced heart block (level 2 or 3), unless pacemaker implanted; Uncontrolled hypotension; Acute cerebrovascular pathologies; Weight < 10 kg; Patients with nasal obstruction; Parental refusal of DEX administration; Minors under guardianship; Minors under judicial sanction.